Xilio Therapeutics (XLO)
US Market

Xilio Therapeutics (XLO) Financial Statements


Xilio Therapeutics Financial Overview

Xilio Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.266; its P/E ratio is -0.91; Xilio Therapeutics is scheduled to report earnings on August 8, 2023, and the estimated EPS forecast is $-0.87. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue--$ 0.00$ 0.00$ 0.00
Gross Profit-----
EBIT$ -22.65M$ -22.48M$ -20.21M$ -24.55M$ -21.22M
EBITDA$ -22.15M$ -21.99M$ -19.73M$ -24.11M$ -20.78M
Net Income Common Stockholders$ -22.65M$ -22.47M$ -19.79M$ -24.61M$ -21.35M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 93.30M$ 120.39M$ 139.14M$ 159.41M$ 176.96M
Total Assets$ 111.50M$ 139.16M$ 157.41M$ 178.13M$ 196.35M
Total Debt$ 18.11M$ 19.94M$ 20.10M$ 20.25M$ 20.40M
Net Debt$ -75.19M$ -100.45M$ -119.05M$ -139.16M$ -156.56M
Total Liabilities$ 26.71M$ 33.52M$ 31.12M$ 33.91M$ 30.23M
Stockholders Equity$ 84.79M$ 105.65M$ 126.30M$ 144.22M$ 166.12M
Cash Flow-
Free Cash Flow$ -25.42M$ -18.73M$ -20.24M$ -17.53M$ -21.09M
Operating Cash Flow$ -25.25M$ -18.22M$ -19.91M$ -16.76M$ -20.84M
Investing Cash Flow$ -170.00K$ -509.00K$ -333.00K$ -771.00K$ -254.00K
Financing Cash Flow$ -1.69M$ -21.00K$ -22.00K$ -21.00K$ -5.00K
Currency in USD

Xilio Therapeutics Earnings and Revenue History

Xilio Therapeutics Debt to Assets

Xilio Therapeutics Cash Flow

Xilio Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis